RxDoctor Payments Data

Mansur Assaad

Pulmonary Disease · Akron, OHNPI 1972034072

Payments from drug & device makers

$2,462in general payments, 2019–2025

Across 69 payments — averaging $35.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$869
  • GSK$746
  • Grifols USA, LLC$248
  • Verona Pharma, Inc.$123
  • Medical Device Business Services, Inc.$61
  • AstraZeneca$56
  • plus $358 from 15 others

What the payments were for

  • Travel & lodging$57823%
  • Food & beverage$1,88477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 50th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$43,897
Medicare patients
183
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter155$131,560
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$40,230
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$29,345
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$20,465
Spiriva RespimatTiotropium Bromide25$16,115
Combivent RespimatIpratropium/Albuterol Sulfate17$7,115
Albuterol Sulfate HfaAlbuterol Sulfate215$6,333
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$3,888
Varenicline Tartrate16$3,258
Wixela InhubFluticasone Propion/Salmeterol20$2,488
Fluticasone Propionate47$725
Montelukast Sodium47$313
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$141
Prednisone28$58
Azithromycin11$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$746$160,906208 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$50$43,69484 claims
AstraZenecaBreztri Aerosphere$56$40,23047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →